Please ensure Javascript is enabled for purposes of website accessibility

Why Intra-Cellular Therapies Is Skyrocketing Today

By Brian Feroldi - Aug 23, 2017 at 12:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares roar higher after the company provides investors with some good regulatory news.

What happened

Intra-Cellular Therapies (ITCI -6.05%), a clinical-stage biopharma focused on diseases of the central nervous system, rose more than 26% as of 11:35 a.m. EDT Wednesday. The big jump came in response to the company sharing some upbeat regulatory news related to its lead compound lumateperone.

So what

Management let investors know that the FDA has completed its review of the additional data that was submitted related to its nonclinical animal toxicology studies. The agency had previously raised concerns about lumateperone's safety since elevated levels of drug-related metabolites that were found in certain species of animal. In response, they asked Intra-Cellular to provide additional data to help show that the drug was safe for use in humans.

Investors learned on Wednesday that Intra-Cellular presented "adequate data to support its position that the metabolic pathway in the animal species is distinctive from humans, which indicates that the toxicity observed in the animal species is not relevant to humans."

In response to this good news, management said it remains on plan to submit the drug for approval as a hopeful treatment of schizophrenia by mid-2018.

Given the update, it is easy to understand why traders are cheering.

A man in a suit giving thumbs up with a medical professional in the background.

Image source: Getty Images.

Now what

There's no doubt that investors were relieved to hear this news. After all, lumateperone is the company's lead product candidate, so if it was going to be pulled over potential safety issues then it would have blown a hole in the bull case for owning the company's stock.

Does this mean it will be smooth sailing for investors from here? That's always a possibility, that caution is warranted. Schizophrenia is a crowded disease state that companies like Bristol-Myers Squibb, AstraZeneca, and Johnson & Johnson have targeted with success for years. Since lumateperone's phase 3 data showed that it failed to outperform a placebo, I have a hard time believing the drug will be able to win over providers and insurers even if it does manage to gain FDA approval. For that reason, I think the smart move is to look elsewhere for investment opportunities.

Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intra-Cellular Therapies, Inc. Stock Quote
Intra-Cellular Therapies, Inc.
ITCI
$53.57 (-6.05%) $-3.45
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$66.64 (3.08%) $1.99
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$165.30 (-1.10%) $-1.84
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$75.57 (1.49%) $1.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.